What is Parkinson's Phase 3 Study Safinamide?

Category: Others

false

See also: Clinical Trial

NCT01187966 is a double-blind, placebo-controlled study to determine the efficacy and safety of a low and high dose of safinamide, as add-on therapy, in patients with idiopathic Parkinson's disease with motor fluctuations, treated with levodopa. Other study ID: NW-1015/016/III/2006.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 0
Moderate 1
Mild 1
None 1

Commonly reported side effects and conditions associated with Parkinson's Phase 3 Study Safinamide

Side effect Patients
Moodiness 1

Why patients stopped taking Parkinson's Phase 3 Study Safinamide

Multiple reasons could be selected

Reason Patients
Doctor's advice 1
See 1 patient who's stopped using Parkinson's Phase 3 Study Safinamide

Duration

Stopped using Parkinson's Phase 3 Study Safinamide

Duration Patients
1 - 6 months 1
Adherence
Adherence Evaluations
Always 3
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 1
A little hard to take 1
Not at all hard to take 1
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 3
Not specified 0
Last updated:
There are no evaluations for Parkinson's Phase 3 Study Safinamide.